000276333 001__ 276333
000276333 005__ 20240229155000.0
000276333 0247_ $$2doi$$a10.1016/j.ijrobp.2023.05.035
000276333 0247_ $$2pmid$$apmid:37244626
000276333 0247_ $$2ISSN$$a0360-3016
000276333 0247_ $$2ISSN$$a1879-355X
000276333 0247_ $$2altmetric$$aaltmetric:149528439
000276333 037__ $$aDKFZ-2023-01063
000276333 041__ $$aEnglish
000276333 082__ $$a610
000276333 1001_ $$aForster, Tobias$$b0
000276333 245__ $$aNon-inferiority of local control and comparable toxicity of intensity-modulated radiotherapy with simultaneous integrated boost in breast cancer: 5-year results of the IMRT-MC2 phase III trial: IMRT-SIB is non-inferior to 3-D-CRT-seqB in RT for BC patients.
000276333 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2023
000276333 3367_ $$2DRIVER$$aarticle
000276333 3367_ $$2DataCite$$aOutput Types/Journal article
000276333 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1698406219_6648
000276333 3367_ $$2BibTeX$$aARTICLE
000276333 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276333 3367_ $$00$$2EndNote$$aJournal Article
000276333 500__ $$a2023 Nov 15;117(4):857-868 / #LA:E050#
000276333 520__ $$aThe IMRT-MC2 trial was conducted to demonstrate non-inferiority of conventionally fractionated intensity-modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) to 3-D-conformal radiotherapy with sequential boost (3-D-CRT-seqB) for adjuvant breast radiotherapy.A total of 502 patients were randomized between 2011 and 2015 for the prospective, multicenter, phase-III-trial (NCT01322854). 5-year results of late toxicity (LENT-SOMA), overall survival, disease-free survival, distant disease-free survival, cosmesis (Harvard scale) and local control (non-inferiority margin at hazard ratio of 3.5) were analyzed after a median follow-up of 62 months.The 5-year LC rate for the IMRT-SIB arm was non-inferior to the control arm (98.7% vs. 98.3%, respectively; HR 0.582, 95%-CI: [0.119-2.375], p=0.4595). Furthermore, there was no significant difference in overall survival (97.1% versus 98.3%, respectively; HR 1.235, 95%-CI: [0.472-3.413], p=0.6697), disease-free survival (95.8% versus 96.1%, respectively; HR 1.130, 95%-CI: [0.487-2.679], p=0.7758) and distant disease-free survival (97.0% versus 97.8%, respectively; HR 1.667, 95%-CI: [0.575-5.434], p=0.3601). After 5 years, late toxicity evaluation and cosmetic assessment further showed no significant differences between treatment arms.The 5-year results of the IMRT-MC2 trial provide strong evidence, that the application of conventionally fractionated simultaneous integrated boost irradiation for breast cancer patients is both safe and effective with non-inferior local control compared to 3-D-conformal radiotherapy with sequential boost.
000276333 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000276333 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276333 650_7 $$2Other$$a3-D-conformal radiotherapy
000276333 650_7 $$2Other$$a5-year follow-up
000276333 650_7 $$2Other$$aBreast cancer
000276333 650_7 $$2Other$$aintensity-modulated radiotherapy (IMRT)
000276333 650_7 $$2Other$$alocal control
000276333 650_7 $$2Other$$aoverall survival
000276333 650_7 $$2Other$$asequential boost irradiation
000276333 650_7 $$2Other$$asimultaneously integrated boost (SIB)
000276333 7001_ $$aKöhler, Clara$$b1
000276333 7001_ $$aDorn, Melissa$$b2
000276333 7001_ $$aHäfner, Matthias Felix$$b3
000276333 7001_ $$aArians, Nathalie$$b4
000276333 7001_ $$aKönig, Laila$$b5
000276333 7001_ $$aHarrabi, Semi Ben$$b6
000276333 7001_ $$aSchlampp, Ingmar$$b7
000276333 7001_ $$aWeykamp, Fabian$$b8
000276333 7001_ $$aMeixner, Eva$$b9
000276333 7001_ $$aLang, Kristin$$b10
000276333 7001_ $$aHeinrich, Vanessa$$b11
000276333 7001_ $$aWeidner, Nicola$$b12
000276333 7001_ $$aHüsing, Johannes$$b13
000276333 7001_ $$aWallwiener, Markus$$b14
000276333 7001_ $$aGolatta, Michael$$b15
000276333 7001_ $$aHennigs, André$$b16
000276333 7001_ $$aHeil, Jörg$$b17
000276333 7001_ $$aHof, Holger$$b18
000276333 7001_ $$aKrug, David$$b19
000276333 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b20$$udkfz
000276333 7001_ $$0P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aHörner-Rieber, Juliane$$b21$$eLast author$$udkfz
000276333 773__ $$0PERI:(DE-600)1500486-7$$a10.1016/j.ijrobp.2023.05.035$$gp. S0360301623005230$$n4$$p857-868$$tInternational journal of radiation oncology, biology, physics$$v117$$x0360-3016$$y2023
000276333 909CO $$ooai:inrepo02.dkfz.de:276333$$pVDB
000276333 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000276333 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c59ff25b48c192ed3fd4ad3a4bc9b9c0$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000276333 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000276333 9141_ $$y2023
000276333 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-17
000276333 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-17
000276333 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-17
000276333 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-24$$wger
000276333 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000276333 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000276333 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000276333 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000276333 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-24
000276333 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J RADIAT ONCOL : 2022$$d2023-08-24
000276333 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000276333 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-24
000276333 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-24
000276333 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J RADIAT ONCOL : 2022$$d2023-08-24
000276333 9202_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000276333 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000276333 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000276333 980__ $$ajournal
000276333 980__ $$aVDB
000276333 980__ $$aI:(DE-He78)E050-20160331
000276333 980__ $$aI:(DE-He78)HD01-20160331
000276333 980__ $$aUNRESTRICTED